Acutaas Chemicals Q1 FY27: Result date, call, setup 2026

Why Acutaas Chemicals’ Q1 FY27 update matters

Acutaas Chemicals Limited is entering the Q1 FY 2026-27 results window after a year of strong sequential growth and capacity expansion, as investors focus on whether margins and growth trends hold. The company has scheduled key events on July 24, 2026, including a board meeting and an earnings conference call. In the run-up, the stock has been quoted at multiple levels across the provided updates, including Rs 3,654.2 and Rs 3,695, highlighting active tracking into results season. Market capitalisation figures in the same set of notes also vary, with references such as Rs 29,917.37 crore and Rs 30,212 crore, and another snapshot listing Rs 22.4K crore alongside a P/E of 62.8.

Result date and board meeting details

As per the provided disclosure, Acutaas Chemicals will hold its board meeting on July 24, 2026, to consider the audited financial results. This makes July 24 a key date for investors positioning ahead of the broader July-August results season. Separately, the company has also communicated an earnings conference call on the same date to discuss its unaudited financial results for Q1 FY27. The quarter under discussion is the first quarter ended June 30, 2026. Investors typically monitor exchange filings (NSE/BSE) for the final timing and documents, especially when different sources reference “indicative” windows such as July-August 2026.

Earnings call: time, host, and management 참석

The earnings conference call is scheduled for Friday, July 24, 2026, at 4:00 PM IST. It is hosted by Nuvama Wealth Management and is expected to feature senior leadership including Chairman and Managing Director Naresh Patel, CFO Bhavin Shah, and President (Strategy) Abhishek Patel. The call is positioned as a forum for investors to review the company’s Q1 FY27 performance and ask questions. The details also include a direct contact for further information via Archit Joshi at Archit.Joshi@nuvama.com.

Dial-in numbers for investors

Participants can join the call using the following dial-in access numbers:

FY26 quarterly run-rate: revenue climbed from Q1 to Q4

The company’s FY2025-26 revenue trajectory showed strong momentum through the year, rising from Rs 207.24 crore in Q1 to Rs 432.75 crore by Q4. The Q4 revenue of Rs 432.75 crore represented sequential growth from Rs 393.2 crore reported in Q3. In the same Q4 period, PAT was reported at Rs 131.76 crore, compared with Rs 62.48 crore in Q4 FY2024-25, indicating sharp year-on-year improvement. Consolidated quarterly commentary in the notes adds that net sales in March 2026 were Rs 432.75 crore, up 40.28% from Rs 308.48 crore in March 2025.

Profitability snapshot: EBITDA, EPS, and cost line items

For March 2026, the provided consolidated set includes EBITDA of Rs 194.62 crore, up 114.48% from Rs 90.74 crore in March 2025. EPS is noted at Rs 16.09 in March 2026 versus Rs 7.80 in March 2025. A separate quarterly table comparing Jun 2025 and Mar 2026 lists total revenue at Rs 207.24 crore for Jun 2025 and Rs 432.75 crore for Mar 2026, alongside operating income of Rs 42.78 crore and Rs 173.88 crore respectively. The same table lists total operating expense of Rs 164.46 crore (Jun 2025) and Rs 258.87 crore (Mar 2026), and depreciation/amortisation of Rs 8.13 crore and Rs 9.63 crore.

Key quarterly financials available in the notes

The following table reproduces the quarter-level figures explicitly provided in the dataset (all figures in Rs crore):

FY26 full-year numbers and what they indicate

The notes also include FY26 financial highlights presented in lakh, which translate into Rs crore for easier comparison. Total income for FY26 is stated at Rs 1,380.95 crore versus Rs 1,023.80 crore in FY25, and revenue from operations at Rs 1,339.37 crore versus Rs 1,006.88 crore. A standalone set shows total income of Rs 1,369.67 crore (FY26) and revenue from operations of Rs 1,323.79 crore, with standalone PAT of Rs 366.17 crore compared with Rs 159.55 crore in FY25. Taken together, the annual data aligns with the quarter-by-quarter narrative of higher scale and improved profitability through FY26.

Guidance and capex: what’s stated, and what isn’t

The dataset references company guidance around 25% CAGR revenue growth, with notes indicating this is expected until at least FY28 and that the company is open to revising upward if business potential exceeds expectations. It also cites an EBITDA margin expectation to be maintained at FY26 levels, with one note referencing about 42% quarterly and about 35% annual levels. For FY27, planned capex is cited around Rs 90 crore to Rs 100 crore, including about Rs 50 crore spillover from FY26 and about Rs 40 crore maintenance capex, with additional R&D centre costs not finalised in the same notes. Importantly, the same material states there is no explicit mention of new fundraising through debt or equity in the provided transcripts for the current or near future.

Market checks to watch into the print

Ahead of results, one snapshot in the notes places Acutaas Chemicals at Rs 3,695 with a market capitalisation of Rs 30,212 crore and a “not meaningful” P/E, while another lists P/E at 62.8 and market cap at Rs 22.4K crore. Another line shows “3,268.60 - 8.60 (-0.26%)”, and a separate historical reference says the shares closed at Rs 2,594.10 on April 29, 2026 (NSE). Because these are pulled from different points and sources, investors typically use the latest NSE/BSE quote and the company’s filings for the definitive reference. The notes also caution that quarterly financials for this cycle may not yet be fully available on data partners and suggest tracking Screener.in and exchange filings directly, and cross-checking figures before making investment decisions.

What to track on July 24

Investors will likely focus on whether the company can sustain the FY26 run-rate after revenue scaled from Rs 207.24 crore (Q1 FY26) to Rs 432.75 crore (Q4 FY26), and whether margins remain aligned with the FY26 guidance cited in the notes. The board meeting on July 24, 2026 is expected to be the key corporate event for financial approvals, while the 4:00 PM IST call provides a structured forum for management commentary. Any clarifications on capex phasing, spillover execution from FY26, and updates to growth guidance are likely to be closely watched, but only confirmed disclosures should be relied upon. The next concrete step for investors is to monitor the NSE/BSE filing on July 24 for the results document and accompanying notes, alongside the conference call discussion.